| The Renal Cell Carcinoma Drug Market Will Experience Robust 3.7 Percent Annual ... - BioMedReports (subscription) |
|
|
BioMedReports (subscription) (BUSINESS WIRE)--Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the renal cell carcinoma drug market will experience robust 3.7 percent annual growth from 2010 to 2020 in ... The Renal Cell Carcinoma Drug Market Will Experience Robust 3.7 Percent Annual ... MarketWatch (press release) Through 2020, Genentech/Roche/Chugai's Avastin Will Be Minimally Challenged as |